Mesoblast (NASDAQ:MESO) Stock Price Down 4.2% - Time to Sell?

Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price dropped 4.2% during trading on Monday . The company traded as low as $9.89 and last traded at $10.01. Approximately 78,595 shares traded hands during trading, a decline of 71% from the average daily volume of 273,854 shares. The stock had previously closed at $10.44.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald upgraded shares of Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Mesoblast Trading Up 1.9%

The company has a current ratio of 0.96, a quick ratio of 0.63 and a debt-to-equity ratio of 0.22. The stock's 50-day simple moving average is $11.31 and its 200-day simple moving average is $13.99.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MESO. Barclays PLC purchased a new stake in shares of Mesoblast in the 4th quarter worth about $38,000. Lindbrook Capital LLC grew its position in shares of Mesoblast by 70.9% in the 4th quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after buying an additional 901 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Mesoblast in the 4th quarter worth about $50,000. BNP Paribas Financial Markets grew its position in shares of Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after buying an additional 2,597 shares during the period. Finally, Advisors Preferred LLC grew its position in shares of Mesoblast by 224.9% in the 1st quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock worth $54,000 after buying an additional 3,169 shares during the period. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.